KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$4.5 million.

  • Neogenomics' Net Cash Flow fell 19025.9% to -$4.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$207.4 million, marking a year-over-year decrease of 94567.77%. This contributed to the annual value of -$207.4 million for FY2025, which is 94567.77% down from last year.
  • Neogenomics' Net Cash Flow amounted to -$4.5 million in Q4 2025, which was down 19025.9% from $9.4 million recorded in Q3 2025.
  • Over the past 5 years, Neogenomics' Net Cash Flow peaked at $372.5 million during Q1 2021, and registered a low of -$250.2 million during Q2 2021.
  • For the 5-year period, Neogenomics' Net Cash Flow averaged around -$4.6 million, with its median value being -$3.7 million (2022).
  • Per our database at Business Quant, Neogenomics' Net Cash Flow soared by 133044.81% in 2023 and then tumbled by 92610.59% in 2025.
  • Neogenomics' Net Cash Flow (Quarter) stood at -$26.9 million in 2021, then surged by 89.05% to -$2.9 million in 2022, then soared by 1330.45% to $36.2 million in 2023, then crashed by 86.15% to $5.0 million in 2024, then tumbled by 190.26% to -$4.5 million in 2025.
  • Its Net Cash Flow stands at -$4.5 million for Q4 2025, versus $9.4 million for Q3 2025 and -$191.4 million for Q2 2025.